Open AccessWeight loss effect of glucagon‐like peptide‐1 mimetics on obese/overweight adults without diabetes: A systematic review and meta‐analysis of randomized controlled trials胰高血糖素样肽‐1类似物对非糖尿病肥胖/超重成人的减重作用：一篇对随机对照试验进行的系统评价及meta分析
Author(s) -
Zhang Fang,
Tong Yuzhen,
Su Na,
Li Yi,
Tang Lizhi,
Huang Li,
Tong Nanwei
Publication year - 2015
Publication title -
journal of diabetes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.949
H-Index - 43
eISSN - 1753-0407
pISSN - 1753-0393
DOI - 10.1111/1753-0407.12198
Subject(s) - medicine , liraglutide , overweight , weight loss , meta analysis , randomized controlled trial , body mass index , diabetes mellitus , type 2 diabetes , obesity , confidence interval , endocrinology
Background Glucagon‐like peptide‐1 receptor agonists ( GLP‐1RAs ) benefit weight maintenance for diabetic patients. We performed a systematic review to evaluate its weight loss effect on obese/overweight patients without diabetes in randomized controlled trials ( RCTs ). Methods Literature updated to M ay 5, 2014 from C ochrane L ibrary, MEDLINE , EMBASE and reference lists from relevant articles were identified. RCTs with GLP ‐1 mimetics treating obese/overweight adults without diabetes for at least 12 weeks were assessed. Studies lacking primary measurements were excluded. Three authors extracted data independently. Either fixed‐effect or random‐effect models were used to calculate weighted mean differences ( WMDs ), combined relative risks ( RR ) and 95% confidence interval ( CI ) in meta‐analyses. Intertrial heterogeneity across studies was examined by I 2 and Q statistics. Results A total of 1345 individuals retrieved from eight studies were involved and all included trials were of mild‐to‐moderate bias risks. Participants in GLP‐1RA groups achieved a larger weight loss than those in control groups (−2.85 kg, 95% CI −3.55 to −2.14), and liraglutide may work in a dose‐dependent fashion. GLP‐1RAs also reduced body mass index ( BMI ) and waist circumferences ( WC ) and benefited systolic blood pressure and triglyceride regulation. But GLP‐1RAs were associated with increased nausea and vomiting events. Conclusions GLP ‐1 mimetics induce a weight loss in addition to BMI and WC reduction in obese/overweight adults without diabetes. Further long‐term randomized trials and basic studies are required to investigate the mechanisms.